Lotus Pharmaceutical Co Ltd (1795) - Total Liabilities
Based on the latest financial reports, Lotus Pharmaceutical Co Ltd (1795) has total liabilities worth NT$82.37 Billion TWD (≈ $2.60 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Lotus Pharmaceutical Co Ltd (1795) equity growth momentum to track the company's year-over-year net asset growth rate.
Lotus Pharmaceutical Co Ltd - Total Liabilities Trend (2009–2025)
This chart illustrates how Lotus Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See Lotus Pharmaceutical Co Ltd (1795) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Lotus Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Lotus Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Riyue Heavy Industry Co Ltd
SHG:603218
|
China | CN¥3.94 Billion |
|
Kernel Holding SA
WAR:KER
|
Poland | zł1.19 Billion |
|
Yantai Zhenghai Magnetic Mat
SHE:300224
|
China | CN¥5.05 Billion |
|
Dalian Huarui Heavy Industry Group Co Ltd
SHE:002204
|
China | CN¥19.40 Billion |
|
Corporativo GBM S.A.B. de C.V
MX:GBMO
|
Mexico | MX$54.26 Billion |
|
SPG Co. Ltd
KQ:058610
|
Korea | ₩170.49 Billion |
|
Nanjing Hanrui Cobalt Co Ltd
SHE:300618
|
China | CN¥4.11 Billion |
|
ShenZhen Kondarl Group Co Ltd
SHE:000048
|
China | CN¥6.32 Billion |
Liability Composition Analysis (2009–2025)
This chart breaks down Lotus Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Lotus Pharmaceutical Co Ltd (1795) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.57 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.46 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.78 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lotus Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lotus Pharmaceutical Co Ltd (2009–2025)
The table below shows the annual total liabilities of Lotus Pharmaceutical Co Ltd from 2009 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | NT$82.37 Billion ≈ $2.60 Billion |
+335.36% |
| 2024-12-31 | NT$18.92 Billion ≈ $596.11 Million |
+20.84% |
| 2023-12-31 | NT$15.66 Billion ≈ $493.31 Million |
0.00% |
| 2022-12-31 | NT$15.66 Billion ≈ $493.32 Million |
+54.22% |
| 2021-12-31 | NT$10.15 Billion ≈ $319.88 Million |
-7.76% |
| 2020-12-31 | NT$11.01 Billion ≈ $346.81 Million |
+8.20% |
| 2019-12-31 | NT$10.17 Billion ≈ $320.54 Million |
+41.84% |
| 2018-12-31 | NT$7.17 Billion ≈ $225.99 Million |
-9.91% |
| 2017-12-31 | NT$7.96 Billion ≈ $250.85 Million |
+15.68% |
| 2016-12-31 | NT$6.88 Billion ≈ $216.86 Million |
+1.65% |
| 2015-12-31 | NT$6.77 Billion ≈ $213.33 Million |
-9.22% |
| 2014-12-31 | NT$7.46 Billion ≈ $235.00 Million |
+1354.11% |
| 2013-12-31 | NT$512.97 Million ≈ $16.16 Million |
+14.56% |
| 2012-12-31 | NT$447.79 Million ≈ $14.11 Million |
-14.66% |
| 2011-12-31 | NT$524.73 Million ≈ $16.53 Million |
+6.27% |
| 2010-12-31 | NT$493.75 Million ≈ $15.56 Million |
+97.35% |
| 2009-12-31 | NT$250.19 Million ≈ $7.88 Million |
-- |
About Lotus Pharmaceutical Co Ltd
Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, central nervous system, cardiovascular diseases, woman health, and anti-obesity. The company also engages in retail of clinical machines;… Read more